||Recombinant Human VTN (Accession # AAH05046.1) Asp20-Leu478 was produced in Mouse myeloma cell line, NS0-derived.
|Predicted N Terminal:
||Lyophilized from a 0.2 µm filtered solution in Tris and NaCl.
||Measured by the ability of the immobilized protein to support the adhesion of B16-F1 mouse melanoma cells.When 5 x 10^4 cells/well are added to Vitronectin coated plates (5 µg/mL with 100 µL/well), approximately >55% will adhere after 30 minutes at 37 °C. Optimal concentration depends on cell type as well as the application or research objectives..
||Recombinant Human VTN has a calculated MW of 52.3 kDa. In SDS-PAGE migrates as 70-80 kDa, reducing conditions.
||>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).